Inactive Instrument

EXMceuticals Inc.

EXM

CA30207T1049

EXMceuticals Inc. Announces Executive Changes

January 14, 2020 at 02:00 pm

EXMceuticals Inc. has appointed Paulo Martins as Chief Executive Officer and Country Director of its operations in Portugal. The Company announced the resignations of Messrs. Michel Passebon and Scott Davis.

Jonathan Summers will act as interim CEO until a successor is appointed.

Latest news about EXMceuticals Inc.

An unknown buyer acquired EXMceuticals Portugal Lda from EXMceuticals Inc. for €0.08 million.	04/04/22	CI
Global Cannabinoids Inc. cancelled the acquisition of EXMceuticals Inc..	09/01/22	CI
EXMceuticals Inc. Announces CEO Changes	22/12/21	CI
EXMceuticals Inc. Announces Resignation of Board Members	01/07/21	CI
Exmceuticals Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021	31/05/21	CI
Global Cannabinoids and EXMceuticals Inc. Announce Management Appointments for the Combined Coampny	04/03/21	CI
EXMceuticals Inc. announced that it expects to receive CAD 6 million in funding	02/03/21	CI
Global Cannabinoids entered into an exclusive non-binding letter of intent to acquire EXMceuticals Inc. in a reverse merger transaction for CAD 33.6 million.	02/03/21	CI
EXMceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2020	27/01/21	CI
An unknown buyer signed an agreement to acquire 70% stake in Prime Ranchers Limited from EXMceuticals Inc. for $0.15 million.	28/12/20	CI
EXMceuticals Inc. Auditor Raises 'Going Concern' Doubt	28/12/20	CI
Exmceuticals Inc. Announces Receipt of COVID-19 Research Grant and Acceleration of Portuguese Activities	08/09/20	CI
EXMceuticals Inc. announced that it has received $0.030467 million in funding	30/08/20	CI
EXMceuticals Inc. Announces Advancement of R&D Operations in Portugal and Efforts to Fight Covid-19 Pandemic	25/08/20	CI
EXMceuticals Inc. announced that it expects to receive $0.030467 million in funding	19/08/20	CI
EXMceuticals Inc. announced that it has received $0.100702 million in funding	18/08/20	CI
EXMceuticals Inc. announced that it expects to receive $0.100702 million in funding	05/08/20	CI
EXMceuticals Inc. announced that it has received CAD 1.036 million in funding	21/07/20	CI
Exmceuticals Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020	03/07/20	CI
EXMceuticals Inc. cancelled the acquisition of MM Ltd.	29/06/20	CI
EXMceuticals Inc. Announces Supply Agreement for THC Distillate	11/06/20	CI
Exmceuticals Inc. Secures Supply & Offtake Agreements-In-Principle for Proposed Portugal Refinery	07/05/20	CI
EXMceuticals Inc. Announces First Closing of Loan Agreement	25/03/20	CI
EXMceuticals Inc. Announces Directorship Changes	03/03/20	CI
Exmceuticals Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2019	02/03/20	CI

Chart EXMceuticals Inc.

Duration

Period

More charts

Company Profile

EXMceuticals Inc. is a bio-sciences company that is focused on the production of cannabinoid formulations. The Company operates through its geographic segments, which include Canada, Portugal, Uganda and Netherlands. The Company's subsidiaries include EXMceuticals Inc., EXMceuticals Holdings B.V, EXMceuticals Portugal, LDA and EXMceuticals Portugal II, Unipessoal Lda.

Sector

Pharmaceuticals

More about the company